SCHEMBL16635676

SCHEMBL16635676

Cc1nc(C2CCC(F)CC2C(=O)O)c(-c2ccc(N3CCOCC3)cc2)s1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CFTR P13569 10/20 0.39
JAK2 O60674 2/20 0.39
JAK1 P23458 1/20 0.39
CDK2 P24941 2/20 0.38
AURKA O14965 1/20 0.38
CDK4 P11802 1/20 0.38
AURKB Q96GD4 1/20 0.38
FFAR4 Q5NUL3 1/20 0.36
CCNT1 O60563 1/20 0.36
CDK1 P06493 1/20 0.36
CCNB1 P14635 1/20 0.36
CCNE1 P24864 1/20 0.36
CDK7 P50613 1/20 0.36
CDK9 P50750 1/20 0.36
CCNH P51946 1/20 0.36
PPARD Q03181 2/20 0.35
ADORA2A P29274 1/20 0.35
ADORA1 P30542 1/20 0.35
KDM4E B2RXH2 1/20 0.35
MEN1 O00255 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16635965 1.00 CFTR (0.39) CFTRJAK2JAK1CDK2AURKA
SCHEMBL18531338 0.91 PARP1 (0.38) CFTRJAK2JAK1CDK2AURKA
SCHEMBL16635820 0.90 ADORA2A (0.39) CFTRJAK2JAK1CDK2AURKA
SCHEMBL16635822 0.90 ADORA2A (0.39) CFTRJAK2JAK1CDK2AURKA
SCHEMBL24018942 0.85 CTSK (0.46) JAK2JAK1CDK2CDK9JAK3
SCHEMBL16636423 0.84 CTSK (0.37) CFTRJAK2JAK1CDK2AURKA
SCHEMBL16635777 0.83 CTSK (0.53)
SCHEMBL24018857 0.83 CTSK (0.53)
SCHEMBL18531332 0.80 CTSK (0.44) JAK2FFAR4KDM4EALDH1A1JAK3
SCHEMBL18531357 0.80 CTSK (0.36) JAK2FFAR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3054947-B1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK SHARP & DOHME (US) 2021-11-17 EP disclosed
US-9573913-B2 Cathepsin cysteine protease inhibitors MERCK SHARP & DOHME CORP. (US) 2017-02-21 US disclosed
US-20160244417-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2016-08-25 US disclosed
EP-3054947-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS Merck Sharp & Dohme Corp. (US) 2016-08-17 EP disclosed
WO-2015051479-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2015-04-16 WO disclosed
WO-2015054038-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2015-04-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160244417-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS CTSB, CTSS, CTSZ CFTR 837/4885JAK2 3823/4885JAK1 3775/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.